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Abstract
Spinal cord α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) mediate
acute spinal processing of nociceptive and non-nociceptive information, but whether and how their
activation contributes to the central sensitization that underlies persistent inflammatory pain are
still unclear. Here, we examined the role of spinal AMPARs in the development and maintenance
of complete Freund's adjuvant (CFA)-induced persistent inflammatory pain. Intrathecal application
of two selective non-competitive AMPAR antagonists, CFM-2 (25 and 50 μg) and GYKI 52466 (50
μg), significantly attenuated mechanical and thermal hypersensitivities on the ipsilateral hind paw at
2 and 24 h post-CFA injection. Neither CFM-2 nor GYKI 52466 affected the contralateral basal
responses to thermal and mechanical stimuli. Locomotor activity was not altered in any of the drug-
treated animals. CFA-induced inflammation did not change total expression or distribution of
AMPAR subunits GluR1 and GluR2 in dorsal horn but did alter their subcellular distribution. The
amount of GluR2 was markedly increased in the crude cytosolic fraction and decreased in the crude
membrane fraction from the ipsilateral L4–5 dorsal horn at 24 h (but not at 2 h) post-CFA injection.
Conversely, the level of GluR1 was significantly decreased in the crude cytosolic fraction and
increased in the crude membrane fraction from the ipsilateral L4–5 dorsal horn at 24 h (but not at
2 h) post-CFA injection. These findings suggest that spinal AMPARs might participate in the central
spinal mechanism of persistent inflammatory pain.
Background
The  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA)-type ionotropic glutamate receptors
(AMPARs) mediate most fast excitatory synaptic transmis-
sions and play a critical role in synaptic plasticity in the
mammalian central nervous system [1,2]. AMPARs are
tetramers that comprise a combination of four subunits
termed GluR1-4 [3]. Changes in postsynaptic membrane
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trafficking or in synaptic targeting of these AMPAR subu-
nits alter synaptic strength and have been recognized as a
central mechanism underlying various forms of synaptic
plasticity [1,2].
Spinal central sensitization, a specific form of synaptic
plasticity, is a mechanism that underlies the development
and maintenance of pain hypersensitivity after peripheral
inflammation [4,5]. In addition to mediating acute spinal
processing of nociceptive and non-nociceptive informa-
tion, the activation of spinal AMPA/kainate receptors
might contribute to spinal central sensitization under
inflammation-induced persistent pain conditions.
Intrathecal pretreatment with AMPA/kainate receptor
antagonists was shown to markedly reduce thermal
injury-induced mechanical tactile allodynia, second-
phase formalin-induced nociceptive behaviors, and carra-
geenan-induced thermal and mechanical hypersensitivi-
ties [6,7]. Because these antagonists are not highly
selective for AMPARs, it is still unclear whether spinal
AMPARs play a critical role in persistent inflammatory
pain. In addition, these AMPA/kainate receptor antago-
nists also produce unwanted side effects [8], which limit
their therapeutic potential in persistent pain.
Recent evidence suggests that peripheral inflammatory
insults might regulate synaptic trafficking of AMPAR sub-
units in spinal cord. Capsaicin-induced acute visceral
inflammatory insult rapidly increased the amount of
GluR1 protein, but not GluR2 or GluR3 proteins, in the
spinal cord membrane fraction and correspondingly
decreased the level of GluR1 in the cytosolic fraction,
without affecting total GluR1 or GluR2 protein expression
in spinal cord [9]. The level of postsynaptic GluR1, but
not GluR2 or GluR3, at lamina II nonpeptidergic C-fiber
synapses was increased during capsaicin-induced acute
inflammation [10]. Complete Freund's adjuvant (CFA)-
induced persistent inflammation significantly elevates the
amount of GluR1 in the postsynaptic density fraction
from spinal cord [11]. This finding indicates that GluR1
could be recruited to the plasma membrane of spinal cord
neurons by persistent noxious inflammation. A previous
study reported that CFA-induced persistent inflammation
increased expression of GluR1 and GluR2 mRNA and the
density of total GluR1 and GluR2 immunohistochemical
staining in dorsal horn [12], suggesting that the levels of
GluR1 and GluR2 may be increased in both plasma mem-
brane and cytosolic fractions of dorsal horn neurons after
CFA injection. Thus, it is still unclear whether CFA-
induced persistent inflammation, like capsaicin-induced
acute inflammatory insult, leads to changes in synaptic
trafficking of AMPAR subunits in dorsal horn neurons.
Here, we first characterized the role of AMPARs in CFA-
induced persistent inflammatory pain in rats using two
highly selective non-competitive AMPAR antagonists, 1-
(4'-aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-
benzodiazepin-4-one (CFM-2) and 4-(methyl-9H-1,3-
dioxolo [4,5-h][2,3]benzodiazepin-5-yl)-benzenamine
hydrochloride (GYKI 52466) [13-15]. We then examined
whether CFA-induced peripheral inflammation altered
expression and distribution of total GluR1 and GluR2
proteins in dorsal horn. Finally, we determined whether
the amounts of GluR1 and GluR2 proteins were changed
in crude plasma membrane and cytosolic fractions from
dorsal horn during CFA-induced inflammatory pain con-
ditions.
Materials and methods
Animal preparation
Male Sprague-Dawley rats (250–300 g) were housed in
cages on a standard 12:12 h light/dark cycle. Water and
food were available ad libitum until rats were transported
to the laboratory approximately 1 h before experiments.
The animals were used in accordance with protocols that
were approved by the Animal Care and Use Committee at
the Johns Hopkins University and were consistent with
the ethical guidelines of the National Institutes of Health
and the International Association for the Study of Pain.
All efforts were made to minimize animal suffering and to
reduce the number of animals used.
Intrathecal catheters were implanted into animals under
isoflurane anesthesia. A polyethylene (PE-10) tube was
inserted into the subarachnoid space at the rostral level of
the spinal cord lumbar enlargement segment through an
incision at the atlanto-occipital membrane according to
the method described previously [16,17]. The animals
were allowed to recover for 5–10 days before being used
experimentally. Rats showing any neurologic deficits post-
operatively were discarded from the study. The position of
the PE-10 catheter was confirmed in each animal after
behavioral testing.
Experimental drugs
CFA was purchased from Sigma Chemical Co. (St. Louis,
MO). 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, a
competitive AMPA/kainate receptor antagonist), CFM-2
(a selective non-competitive AMPAR antagonist), and
GYKI 52466 (a selective non-competitive AMPAR antago-
nist) were purchased from Tocris Bioscience (Ellisville,
MO). CNQX was dissolved in 0.9% physiologic saline,
whereas CFM-2 and GYKI 52466 were dissolved in 10%
dimethylsulfoxide (DMSO).
CFA-induced persistent inflammatory pain model
To induce persistent inflammatory pain, the rats were
placed under isoflurane anesthesia, and 100 μl of CFA (1
mg/ml Mycobacterium tuberculosis) solution was injected
into the plantar side of one hind paw. Our previous stud-Molecular Pain 2008, 4:67 http://www.molecularpain.com/content/4/1/67
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ies showed that significant CFA-induced thermal and
mechanical pain hypersensitivities appeared at 2 h,
reached a peak level between 6 and 24 h, and were main-
tained for at least 72 h [17]. Therefore, we chose 2 h and
24 h post-CFA injection to represent the development and
maintenance phases of CFA-induced persistent inflamma-
tory pain for the pharmacologic and biochemical studies.
To examine the role of spinal cord AMPARs in persistent
inflammatory pain, two selective competitive AMPAR
antagonists, CFM-2 (5, 25, or 50 μg/10  μl) and GYKI
52466 (50 μg/10 μl) were injected intrathecally followed
by 10 μl of saline to flush the catheter (total volume of the
catheter: 10 μl) at 2 h or 24 h post-CFA injection. To com-
pare the effects of selective and non-selective AMPAR
antagonists on persistent inflammatory pain, a competi-
tive AMPA/kainate receptor antagonist, CNQX (6.1 μg/10
μl), was given according to the same protocol. Saline and
10% DMSO were used as controls. The behavioral tests
described below were performed 1 day before CFA injec-
tion (baseline) and at 20 min after drug administration.
Separate groups of rats were used for the 2-h and 24-h
behavioral tests. The antagonist doses used were based on
data from previous studies [18-21] and our pilot work.
The experimenters were blinded to the treatment groups.
Behavior testing
To measure paw withdrawal response to noxious heat
stimuli, each animal was placed in a Plexiglas chamber on
a glass plate located above a light box. Radiant heat from
a Model 336 Analgesic Meter (IITC, Inc./Life Science
Instruments, Woodland Hills, CA) was applied by aiming
a beam of light through a hole in the light box through the
glass plate to the middle of the plantar surface of each
hind paw. When the animal lifted its foot, the light beam
was turned off. The length of time between the start of the
light beam and the foot lift was defined as the paw with-
drawal latency. Each trial was repeated five times at 5-min
intervals for each paw. A cut-off time of 20 s was used to
avoid paw tissue damage.
To measure paw withdrawal response to repeated
mechanical stimuli, each animal was placed in a Plexiglas
chamber on an elevated mesh screen. A single trial of
mechanical stimuli consisted of eight applications of a
calibrated von Frey filament (8.01 mN, Stoelting Co.,
Wood Dale, IL) within a 2–3-s period. Each trial was
repeated 10 times at 3-min intervals on each hind paw.
The occurrence of hind paw withdrawal in each of these
10 trials was expressed as a percent response frequency,
and this percentage was used as an indication of the
amount of hind paw withdrawal.
Locomotor function testing
To examine whether the antagonists used in behavioral
testing affected the locomotor function, three reflexes
(placing, grasping, and righting) were tested as described
previously [16,22]. In brief, the naïve animals received a
10-μl intrathecal injection of vehicle (saline or 10%
DMSO), CNQX (6.1 μg/10 μl), CFM-2 (50 μg/10 μl), or
GYKI 52466 (50 μg/10 μl). Twenty minutes later, the fol-
lowing tests were performed with the experimenter blind
to drug treatment: (1) Placing reflex: The experimenter
held the rat with hind limbs slightly lower than the fore-
limbs and brought the dorsal surfaces of the hind paws
into contact with the edge of a table. The experimenter
recorded whether the hind paws were placed on the table
surface reflexively; (2) Grasping reflex: The experimenter
placed the rats on a wire grid and recorded whether the
hind paws grasped the wire on contact; (3) Righting reflex:
The experimenter placed the rat's back on a flat surface
and noted whether it immediately assumed the normal
upright position. Scores for placing, grasping, and righting
reflexes were based on counts of each normal reflex exhib-
ited in five trials. In addition, the rat's general behaviors,
including spontaneous activity (e.g. walking and run-
ning), were observed.
Western blot analysis
Expression of GluR1 and GluR2 proteins in the total solu-
ble fraction, crude membrane fraction, and crude
cytosolic fraction was examined. In brief, the animals
were sacrificed by decapitation at 2 and 24 h after injec-
tion of saline (100 μl) or CFA into the plantar side of a
hind paw. Naïve animals were used as controls. The L4–5
spinal cord ipsilateral and contralateral to CFA or saline
injection was removed. The dorsal part of the spinal cord
was separated from the ventral part and collected. Total
soluble fraction, crude membrane fraction, and crude
cytosolic fraction were prepared as described below. The
samples were heated for 5 min at 99°C and then loaded
onto 4% stacking/7.5% separating SDS-polyacrylamide
gels. The proteins were electrophoretically transferred
onto nitrocellulose membrane. The blotting membrane
was blocked with 3% non-fat dry milk for 1 h and incu-
bated overnight at 4°C with rabbit anti-GluR1 (1:200;
Upstate/CHEMICON, Temecula, CA), rabbit anti-GluR2
(1:500; Upstate/CHEMICON), rabbit anti-N-cadherin
(1:1,000; BD Biosciences, Palo Alto, CA), mouse anti-
PSD-95 (1:1,000; Upstate/CHEMICON), or monoclonal
mouse anti-β-actin (1:10,000; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA). N-cadherin and PSD-95 were used
as loading controls and markers for crude membrane frac-
tion, whereas β-actin was used as a loading control for
total soluble fraction and cytosolic fraction. The proteins
were detected with anti-rabbit or anti-mouse secondary
antibody and visualized using the chemiluminescence
reagents provided with the ECL kit (Amersham Pharmacia
Biotech, Piscataway, NJ) and exposure to film. The inten-
sity of blots was quantified with densitometry. The blot
density from naïve animals was set as 100%.Molecular Pain 2008, 4:67 http://www.molecularpain.com/content/4/1/67
Page 4 of 11
(page number not for citation purposes)
Subcellular fractionation of proteins
After tissues were homogenized in lysis buffer (10 mM
Tris-HCl, 250 mM sucrose, 5 mM MgCl2, 2 mM EGTA, 1
mM phenylmethylsulfonyl fluoride, 2 mM sodium
orthovanadate, 1 mM NaF, 1 mM leupeptin, 2 mM pep-
statin A, 1 mM dithiothreitol), the crude homogenates
were centrifuged at 4°C for 15 min at 900 g. The superna-
tant was collected, and the pellet (nuclei and debris frac-
tion) discarded. After the measurement of protein
concentration, 20% of the supernatant was removed and
considered to be the total soluble fraction. The remaining
supernatant (80%) was centrifuged at 37,000 g for 1 h at
4°C. The supernatant was considered to be the crude
cytosolic fraction, and the pellet, the crude plasma mem-
brane fraction. The pellet was dissolved in buffer (10 mM
Tris-HCl, pH 7.4, 1.5% SDS, and 0.1% Triton X-100). Pro-
tein concentrations of the three fractions were measured,
and samples were prepared for Western blotting, as
described above.
Immunocytochemistry
The animals were deeply anesthetized with isoflurane and
perfused with 4% paraformaldehyde in phosphate buffer
(0.1 M, pH 7.4) at 2 or 24 h after saline or CFA injection.
Naïve rats were used as controls. The L4–5 spinal cord seg-
ments were harvested, post-fixed in the same fixative solu-
tion for 2–4 h, cryoprotected by immersion in 30%
sucrose overnight at 4°C, and frozen-sectioned at 25 μm.
Every fourth section was collected (at least 30 sections/
rat). The sections were blocked for 1 h at 37°C in 0.01 M
phosphate-buffered saline (PBS) containing 10% normal
goat serum plus 0.3% Triton X-100. Half of the sections
(approximately 15 sections/rat) were incubated in pri-
mary rabbit antibody for GluR1 (1:500; Upstate/CHEMI-
CON) and the remaining sections in primary mouse
antibody for GluR2 (1:1,000; Upstate/CHEMICON) for
48 h at 4°C. The sections were finally incubated in bioti-
nylated goat anti-rabbit or anti-mouse IgG (1:200; Vector
Laboratories, Burlingame, CA) for 1 h at 37°C followed
by avidin-biotin-peroxidase complex (1:100; Vector) for 1
h at 37°C. The immune reaction product was visualized
by catalysis of 3,3-diaminobenzidine by horseradish per-
oxidase in the presence of 0.01% H2O2.
Immunostained spinal cord sections were quantified with
an Olympus microscope (Olympus, Tokyo, Japan) linked
to a Toshiba 3CCD camera (Toshiba, Japan) and I-Cube
computer image analysis system (I-Cube, Cambridge,
MA). The entire superficial dorsal horn was delimited to
quantify the optical density of GluR1 and GluR2 immu-
noreactivity. Five spinal cord sections randomly selected
from a total of 15 sections from each animal were ana-
lyzed, and the relative optical densities of five sections
were averaged to provide a mean for each animal.
Statistical Analysis
The results from the behavioral tests, Western blotting,
and immunocytochemistry were statistically analyzed
with a one-way or two-way analysis of variance (ANOVA).
Data are presented as mean ± SEM. When ANOVA showed
significant difference, pairwise comparisons between
means were tested by the post hoc Tukey method. Signifi-
cance was set at p < 0.05. The statistical software package
SigmaStat (Systat, Port Richard, CA) was used to perform
all statistical analyses.
Results
Effects of intrathecal selective and nonselective AMPAR 
antagonists on CFA-induced mechanical and thermal 
hypersensitivities
The effect of intrathecal administration of CFM-2 on
mechanical and thermal hypersensitivities in animals at 2
h or 24 h after CFA injection was first examined. Consist-
ent with previous studies [17], CFA injection produced a
significant increase in paw withdrawal frequency in
response to mechanical stimulation (indicating mechani-
cal hypersensitivity; Fig. 1A) and a remarkable decrease in
paw withdrawal latency in response to thermal stimula-
tion (indicating thermal hypersensitivity; Fig. 1C) on the
ipsilateral side at both 2 h (n = 14, 7/test) and 24 h (n =
14, 7/test) post-CFA injection in the vehicle group.
Intrathecal administration of CFM-2 dose-dependently
attenuated CFA-induced mechanical hypersensitivity at 2
h and 24 h post-CFA injection (Fig. 1A). Compared with
the corresponding vehicle-treated groups, the 25-μg dose
of CFM-2 reduced paw withdrawal frequencies by 26% (p
< 0.05) and 35% (p < 0.01) at 2 h and 24 h (n = 6/time
point) post-CFA injection, respectively, and the 50-μg
dose reduced paw withdrawal frequencies by 37% (p <
0.05) and 49% (p < 0.01) at these two time points (n = 6/
time point). Paw withdrawal frequencies after administra-
tion of 5 μg of CFM-2 at 2 h (n = 6) and 24 h (n = 6) post-
CFA injection were not significantly different from those
of the vehicle group at those time points (p > 0.05). Inter-
estingly, only the highest CFM-2 dose (50 μg) signifi-
cantly reduced the CFA-induced thermal hypersensitivity
(Fig. 1C). Compared with vehicle-treated rats, paw with-
drawal latencies were increased by 31% at 2 h post-CFA
injection (n = 6; p < 0.05) and by 70% at 24 h post-CFA
injection (n = 6; p < 0.05). Neither the vehicle nor any of
the three CFM-2 doses significantly altered basal paw
withdrawal responses to mechanical and thermal stimuli
applied to the contralateral hind paw at 2 h or 24 h post-
CFA injection (Fig. 1B,D). Likewise, none of the doses of
CFM-2 significantly affected basal paw withdrawal
responses to mechanical and thermal stimuli in naïve rats
(data not shown).
To further confirm the effect of selective non-competitive
AMPAR antagonists on persistent inflammatory pain, weMolecular Pain 2008, 4:67 http://www.molecularpain.com/content/4/1/67
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intrathecally injected another selective non-competitive
AMPAR antagonist, GYKI 52466 [15], at 2 h and 24 h
post-CFA injection. A 50-μg injection of GYKI 52466 (n =
6/test/time point) attenuated both CFA-induced mechan-
ical and thermal hypersensitivities on the ipsilateral hind
paw (Fig. 2A,E). Paw withdrawal frequencies were 31%
and 38% lower than those of the vehicle-treated group at
2 h (p < 0.05) and 24 h (p < 0.05) post-CFA injection,
respectively (Fig. 2A). Paw withdrawal latencies were 38%
and 92.5% higher than those of the vehicle-treated group
at 2 h (p < 0.05) and 24 h (p < 0.05) post-CFA injection,
respectively (Fig. 2E). Similar to CFM-2, 50 μg GYKI
52466 had no effect on paw withdrawal responses to ther-
mal or mechanical stimuli applied to the contralateral
hind paw at either time point (Fig. 2B,F) or in naïve rats
(data not shown).
CNQX is a non-selective competitive AMPAR antagonist.
Compared with the responses of the vehicle-treated group
(n = 20; 5/test/time point), intrathecal CNQX (6.1 μg) sig-
nificantly reduced CFA-induced mechanical and thermal
hypersensitivities at 2 h (p < 0.01) and 24 h (p < 0.01) after
CFA injection (Fig. 2C,G). However, the same dose of
CNQX also significantly reduced basal paw withdrawal
responses to mechanical stimulation on the contralateral
hind paw at both time points (both p < 0.05; Fig. 2D),
although it had no effect on basal paw withdrawal
responses to thermal stimulation on the contralateral
hind paw after CFA injection (Fig. 2H).
Effects of intrathecal selective and nonselective AMPAR 
antagonists on locomotor functions
To exclude the possibility that the behavioral effects
described above were due to impaired motor functions
caused by these antagonists, we then examined the effects
of CFM-2, GYKI 52466, and CNQX on locomotor func-
tions in naive animals. As indicated in Table 1, at the
doses used, none of the antagonists significantly altered
placing, grasping, or righting reflexes. In addition, no sig-
nificant differences were observed in the rats' general
behaviors (such as walking and running) between the
vehicle-treated and the antagonist-treated groups.
Effect of CFA-induced peripheral inflammation on 
expression and distribution of total GluR1 and GluR2 
proteins in dorsal horn
To further define the involvement of spinal cord AMPARs
in persistent inflammatory pain, we examined whether
CFA-induced inflammation produced the changes in
expression of total GluR1 and GluR2 proteins in total sol-
Effect of intrathecal injection of CFM-2 (5, 25, and 50 μg) on the paw withdrawal responses to mechanical (A and B) and ther- mal (C and D) stimuli on the ipsilateral (A and C) and contralateral (B and D) sides at 2 and 24 h after intraplantar CFA injec- tion Figure 1
Effect of intrathecal injection of CFM-2 (5, 25, and 50 μg) on the paw withdrawal responses to mechanical (A 
and B) and thermal (C and D) stimuli on the ipsilateral (A and C) and contralateral (B and D) sides at 2 and 24 
h after intraplantar CFA injection. Data are presented as mean ± SEM. n = 6 rats/dose/test, except n = 7 for the vehicle-
treated group. # p < 0.05, ## p < 0.01 vs the corresponding vehicle-treated group.
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uble fraction derived from dorsal horn. In the ipsilateral
and contralateral L4–5 dorsal horn, neither total GluR1 nor
total GluR2 protein level was significantly different from
that of naïve animals (n = 4) at 2 and 24 h post-saline (n
= 4/time point) and post-CFA (n = 4/time point) injection
(p > 0.05; Fig. 3A, B).
We next examined whether peripheral inflammatory
insult affected the distribution of total GluR1 and GluR2
immunoreactivities in the spinal dorsal horn at 2 and 24
h after CFA injection. Consistent with previous studies
[12,23,24], GluR1 immunoreactivity was distributed
mainly in laminae I and II, whereas GluR2 immunoreac-
tivity was concentrated in inner lamina II and lamina III
in naïve rats (n = 3). Under high magnification, some
GluR1- and GluR2-positive cell bodies were observed in
both superficial and deep dorsal horn (Fig. 3C). Neither
intraplantar saline nor CFA produced significant changes
in the distribution or optical density of GluR1 and GluR2
immunoreactivities in L4–5 spinal dorsal horn on the ipsi-
lateral or contralateral side at 2 h (p > 0.05) or 24 h (p >
0.05) post-saline (n = 6, 3/time point) or post-CFA (n = 6,
3/time point) injection (Fig. 3D–F).
Effect of CFA-induced peripheral inflammation on the 
levels of GluR1 and GluR2 proteins in plasma membrane 
fraction and cytosolic fraction from dorsal horn
Finally, we examined whether CFA-induced peripheral
inflammation affected the subcellular distribution of
GluR1 and GluR2 proteins in dorsal horn neurons. Quan-
tification of the protein levels revealed that, compared
with the naïve animals (n = 4), the amount of GluR2 in
the CFA-treated group was 90% higher in the cytosolic
fraction (Fig. 4A; p  < 0.01) and correspondingly 26%
lower in the membrane fraction (Fig. 4B; p < 0.05) at 24 h
post-CFA injection (n = 4). Conversely, the amount of
GluR1 was decreased by 25% in the cytosolic fraction (Fig.
4C; p < 0.05) and correspondingly increased by 23% in
the membrane fraction (Fig. 4D; p < 0.05) at 24 h post-
CFA injection (n = 8) compared with the values of the
naïve group (n = 8). Neither the GluR1 nor the GluR2 lev-
els were significantly changed in either the cytosolic (Fig.
4A, C; p > 0.05) or membrane (Fig. 4B, D; p > 0.05) frac-
tion at 2 h post-CFA injection (n = 4). As expected, no sig-
nificant differences were observed between the saline-
treated and naïve groups in either the cytosolic or mem-
brane fractions at 2 or 24 h post-saline injection (Fig. 4; n
= 4–8/time point).
Effects of intrathecal injection of GYKI 52466 (50 μg, n = 6/test/time point, A, B, E, and F) and CNQX (6.1 μg, n = 5/test/time  point, C, D, G, and H) on the paw withdrawal responses to mechanical (A–D) and thermal (E–H) stimuli on the ipsilateral (A,  C, E, and G) and contralateral (B, D, F, and H) sides at 2 and 24 h after intraplantar CFA injection Figure 2
Effects of intrathecal injection of GYKI 52466 (50 μg, n = 6/test/time point, A, B, E, and F) and CNQX (6.1 μg, n 
= 5/test/time point, C, D, G, and H) on the paw withdrawal responses to mechanical (A–D) and thermal (E–H) 
stimuli on the ipsilateral (A, C, E, and G) and contralateral (B, D, F, and H) sides at 2 and 24 h after intra-
plantar CFA injection. Data are presented as mean ± SEM. # p < 0.05, ## p < 0.01 vs the corresponding vehicle-treated 
group.
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Table 1: Effect of selective and non-selective AMPA receptor 
antagonists on locomotor functions
Treated group Placing Grasping Righting
Saline 5 (0) 5 (0) 5 (0)
DMSO (10%) 5 (0) 5 (0) 5 (0)
CNQX (6.1 μg) 5 (0) 5 (0) 5 (0)
CFM-2 (50 μg) 5 (0) 4.8 (0.45) 5 (0)
GYKI 52466 (50 μg) 4.6 (0.25) 5 (0) 5 (0)
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To test the specificity of the fractionation procedure, the
expression levels of a plasma membrane-specific protein
(N-cadherin), a postsynaptic density protein (PSD-95),
and an intracellular protein (β-actin) were assessed in
both crude plasma membrane and cytosolic fractions
from naïve rats (n = 3). Consistent with previous studies
[9,22], N-cadherin and PSD-95 were detected at high lev-
els in the crude plasma membrane fraction but were
barely detectable in the crude cytosolic fraction (Fig. 4E),
whereas β-actin was expressed predominately in the crude
Expression and distribution of total GluR1 and GluR2 in spinal cord dorsal horn Figure 3
Expression and distribution of total GluR1 and GluR2 in spinal cord dorsal horn. A and B: Top: representative 
Western blots showing GluR1 protein (A) and GluR2 protein (B) in total soluble fraction derived from the ipsilateral and con-
tralateral L4–5 dorsal horns of naïve rats (n = 4) and the rats at 2 and 24 h post-saline (S; n = 4/time point) or post-CFA injec-
tion (C; n = 4/time point). Bottom: statistical summary of the densitometric analysis expressed relative to the corresponding 
loading control (β-actin). C: Representative photographs showing the distribution of GluR1 immunoreactive cells (arrow 
heads) in lamina V and of GluR2 immunoreactive cells (arrows) in laminae II-III. Scale bar: 20 μm. D and E: Representative pho-
tographs showing distribution of GluR1 (D) and GluR2 (E) immunoreactivity in the ipsilateral and contralateral L4 dorsal horns 
at 2 and 24 h post-CFA injection. Scale bar: 200 μm. F: Statistical summary of the optical density of GluR1 and GluR2 immuno-
reactivity in the ipsilateral and contralateral L4–5 dorsal horns at 2 and 24 h post-saline (n = 3/time point) or post-CFA (n = 3/
time point) injection. N: naïve (n = 3). Data are presented as mean ± SEM.
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cytosolic fraction (Fig. 4E), indicating that the fractiona-
tion procedure effectively separated cytosolic proteins
from plasma membrane proteins.
Discussion
Peripheral tissue inflammation leads to persistent hyper-
algesia in animals that mimics chronic inflammatory pain
states in humans. Understanding the mechanisms that
underlie persistent inflammatory pain may produce novel
therapeutic strategies for prevention and/or treatment of
clinical inflammatory pain. Although evidence docu-
mented over the last 30 years suggests that AMPARs might
be involved in persistent inflammatory pain, the exact
role of spinal cord AMPARs in this disorder is unclear. Our
study provides pharmacologic evidence that blockade of
spinal cord AMPARs produces marked reversal of
mechanical and thermal hypersensitivities during the
development and maintenance phases of CFA-induced
persistent inflammatory pain. In addition, we show that
CFA-induced peripheral inflammation leads to GluR2
internalization and GluR1 membrane insertion in dorsal
horn neurons, without altering the expression and distri-
The relative levels of GluR2 (A and B) and GluR1 (C and D) in the crude cytosolic (A and C) and plasma membrane fractions  (B and D) from the ipsilateral L4–5 dorsal horn at 2 and 24 h following saline or CFA injection Figure 4
The relative levels of GluR2 (A and B) and GluR1 (C and D) in the crude cytosolic (A and C) and plasma mem-
brane fractions (B and D) from the ipsilateral L4–5 dorsal horn at 2 and 24 h following saline or CFA injection. 
Naïve rats (n = 4–8) were used as a control group. Data are presented as mean ± SEM. n = 4–8 rats/treatment. * p < 0.05, ** p 
< 0.01 vs the corresponding naïve group. E: The specificity of the fractionation procedure. Top: representative Western blots 
showing the expression of N-cadherin, PSD-95, and β-actin in total soluble fraction, plasma membrane fraction, and cytosolic 
fraction from L4–5 dorsal horns of naïve rats (n = 3). Bottom: statistical summary of the densitometric analysis expressed rela-
tive to the corresponding protein levels in the total soluble fraction.
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bution of total GluR1 and GluR2 proteins in dorsal horn.
These findings suggest that spinal cord AMPARs might
play a critical role in the central mechanism of persistent
inflammatory pain.
The therapeutic potential of AMPAR antagonists in per-
sistent pain has been largely overlooked because it is gen-
erally thought that AMPARs are involved primarily in fast
synaptic transmission and acute spinal processing of noci-
ceptive and non-nociceptive inputs in the dorsal horn [4].
For example, some earlier studies showed that intrathecal
injection of competitive AMPA/kainate receptor antago-
nists produced dose-dependent antinociception in the tail
flick test and hot plate test [25] in rats. Moreover, systemic
administration of a competitive AMPA/kainate receptor
antagonist, NBQX, reduced chronic allodynia-like
response in spinally injured rats; however, it also reduced
muscle tone and caused sedation at the dose studied [8].
In our study, intrathecal CNQX, another competitive
AMPA/kainate receptor antagonist, markedly attenuated
CFA-induced mechanical and thermal hypersensitivities
ipsilaterally, but it also significantly reduced basal paw
withdrawal response to mechanical stimulation on the
contralateral hind paw after peripheral inflammation.
These unwanted side effects associated with AMPA/kain-
ate receptor antagonists may prevent them from providing
therapeutic potential in persistent pain.
The present study demonstrates that intrathecally admin-
istered CFM-2 and GYKI 52466, two highly selective non-
competitive AMPAR antagonists [13-15], significantly
reverse CFA-induced mechanical and thermal hypersensi-
tivities on the ipsilateral side, without affecting basal noci-
ceptive responses on the contralateral side. Neither CFM-
2 nor GYKI 52466 at the doses used affected normal noci-
ceptive responses or locomotor function in naïve animals.
These data indicate that CFM-2 and GYKI 52466 at the
doses used affect peripheral inflammation-induced
behavioral reflex sensitization rather than basal behavio-
ral reflex, suggesting a role of spinal cord AMPARs in
mediating the sensitized nociceptive transmission that
occurs under persistent inflammatory pain conditions.
Among the four AMPAR subunits, GluR1 and GluR2 are
the most abundant in dorsal horn, particularly in the
superficial dorsal horn [24,26], where they are highly con-
centrated on the postsynaptic neuronal membranes
[27,28]. We found that CFA injection did not affect the
distribution or optical density of GluR1 and GluR2
immunoreactivity in dorsal horn. This finding is incon-
sistent with a previous report that showed that CFA-
induced peripheral inflammation increased the density of
GluR1 and GluR2 immunoreactivity in dorsal horn [12].
The reason for the discrepancy between the previous and
present results is unclear but might be related to different
primary antibody and immunostaining duration. Quanti-
tative Western blot analyses from the present study and
those of others [29,30] further demonstrated that the
expression levels of total GluR1 and GluR2 proteins were
not significantly changed in dorsal horn under CFA-
induced inflammatory pain conditions. It is very likely
that peripheral inflammatory insult does not alter transla-
tion of GluR1 and GluR2 genes and/or degradation of
their proteins in dorsal horn neurons.
One important observation that we made is that periph-
eral persistent inflammation produces distinct changes in
the levels of GluR1 and GluR2 in plasma membrane and
cytosolic fractions from dorsal horn. Consistent with a
recent study [11], the present study showed that CFA
injection produced GluR1 membrane insertion in dorsal
horn neurons at 24 h post-CFA injection. We also found
that GluR2 was markedly internalized in dorsal horn neu-
rons at 24 h post-CFA injection. Moreover, the number of
internalized GluR2 subunits is likely greater than the
number of GluR1 subunits inserted in the membrane.
Electrophysiological studies from our laboratory and
those of others demonstrated that Ca2+-permeable
AMPARs were significantly increased in the superficial
dorsal horn neurons at 24 and 72 h post-CFA injection
[31,32]. Because only GluR2 determines the properties of
synaptic AMPAR function, particularly Ca2+ permeability
[3], GluR2 internalization might be a major player in
AMPAR subunit trafficking in dorsal horn neurons during
the maintenance of persistent inflammatory pain syn-
dromes.
An unexpected observation in the current study was that
CFA injection did not produce a marked change in the lev-
els of GluR1 and GluR2 in subcellular fractions from dor-
sal horn at 2 h post-CFA injection. The reason for the
discrepancy in AMPAR trafficking at 2 h and 24 h post-
CFA injection is unclear, but it may be related to the lim-
ited sensitivity of Western blotting. It is possible that
GluR1 membrane insertion and GluR2 internalization in
dorsal horn neurons are too minimal at 2 h post-CFA
injection to be detected by this approach. In addition, syn-
aptic AMPAR exchange for intracellular receptors in dorsal
horn neurons may have a long timescale because synaptic
AMPAR trafficking events in vitro and in intact brains have
a slow rate time constant of ~15–18 h [33,34].
The molecular mechanisms by which GluR1 is inserted
into plasma membrane and GluR2 is internalized into
cytoplasm in dorsal horn neurons during the mainte-
nance phase of persistent inflammatory pain are unclear,
but they might be related to inflammation-induced spinal
cord GluR1 and GluR2 phosphorylation. Protein kinase A
phosphorylation of GluR1 Ser845 promotes the surface-
expression of GluR1 in cultured hippocampal neuronsMolecular Pain 2008, 4:67 http://www.molecularpain.com/content/4/1/67
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during activity-dependent long-term potentiation [35]
and might also be responsible for spinal GluR1 mem-
brane insertion in vivo following CFA-induced inflamma-
tion. Similarly, Protein kinase C phosphorylation of
GluR2 at Ser880 disrupts GluR2 binding to its synaptic
anchoring protein ABP/GRIP and promotes GluR2 inter-
nalization in cultured hippocampal neurons [36,37].
Such a mechanism might also contribute to CFA-induced
internalization of GluR2 subunits in vivo. It will be very
important to further elucidate these mechanisms to fully
understand the role of spinal AMPAR trafficking in the
spinal central sensitization that underlies persistent
inflammatory pain.
In conclusion, we demonstrated that selective blockade of
spinal AMPAR activity significantly reduces mechanical
and thermal hypersensitivities during the development
and maintenance of persistent inflammatory pain. We
also showed that GluR2 is likely transported away from
the plasma membrane and GluR1 inserted into plasma
membrane of dorsal horn neurons during the mainte-
nance (but not the development) of persistent inflamma-
tory pain. These findings imply that spinal cord AMPARs
are involved in the central mechanism of persistent
inflammatory pain.
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